Congress funds asthma research targeting racial health disparities

What it does

This bill directs the CDC to expand asthma research, surveillance, and public education, with a focus on disparities affecting Black Americans, Native Americans, Puerto Ricans, and low-income populations. It requires states to develop asthma control plans, mandates annual data collection and reporting on asthma prevalence and outcomes disaggregated by race and ethnicity, and authorizes $70 million over five years for these activities.

Why we flagged it

The bill's operative mechanism is straightforward: it expands CDC authority to conduct asthma surveillance, mandates state planning, and funds public education. The naming after Elijah E. Cummings (a deceased congressman from Maryland) is commemorative, not self-serving, and does not alter the bill's functional purpose.

What the text implies

• The bill's requirement for data disaggregation by race, ethnicity, and geography may expose persistent health disparities in state Medicaid programs, potentially creating political pressure for coverage expansion or policy changes in states with poor asthma outcomes.
• Real-time data exchange between healthcare, schools, and public health entities (Section 317I) creates a new surveillance infrastructure that, while privacy-protected at the individual level, aggregates population-level asthma trends in ways that could inform environmental regulation or housing policy.
• The $70M authorization is modest relative to the $82B annual cost of asthma, suggesting this is a foundational research and surveillance investment rather than a direct treatment or medication subsidy—benefits will accrue over years as data informs policy.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill funds public health infrastructure to address a disease that kills 3,600 Americans annually and costs the economy $82 billion per year, with explicit focus on reducing documented health disparities. It creates no new restrictions on citizens' rights or remedies, imposes no costs on individuals, and establishes transparent data collection to hold government accountable for progress.

Who stands to gain

• CDC contractors and vendors (data systems, surveillance platforms)
• State and local health departments (funding recipients)
• Nonprofit organizations and patient advocacy groups (collaboration partners)

Named in the bill

Centers for Disease Control and Prevention (CDC), National Center for Environmental Health, National Heart, Lung, and Blood Institute, Centers for Medicare & Medicaid Services, Environmental Protection Agency, Department of Housing and Urban Development, Department of Education, Department of Veterans Affairs, Department of Defense, National Institutes of Health

Where it stands

4 cosponsors: 2 Democrats, 2 Republicans.

• Nov 17, 2025 — Introduced · Congress.gov: “Introduced in House”
• Nov 17, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 3 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $200,000 in lobbying spend. A filing names 24 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Debbie Dingell, the sponsor, reported $747,585 in PAC receipts in the 2026 cycle.

• American Lung Association — $120,000 on 1 filing
• Arc of the United States — $80,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.